IM Cannabis (IMCC) Stock Price, Financials & Analysis

Key Stats

Market Cap1.15 Mn

P/E-0.15

P/S0.03

Div. Yield0.00

Total Debt (Qtr)8.49 Mn

Revenue Growth (1y) (Qtr)-40.12

Add ratio to table…

About

IM Cannabis Corp. is an international cannabis company focused on the importation, distribution and sale of medical cannabis products to medical patients in Israel and Germany. The company operates medical cannabis retail pharmacies, online platforms, distribution centers and logistical hubs in Israel through its subsidiaries. In Germany, it imports cannabis and sells through its own IMC branded products and exclusive ultra premium Canadian brands via its subsidiary…

Revenue is generated primarily from the sale of medical cannabis flower and extracts, with additional income from cannabis accessories and related non cannabis items. In the fiscal year ended December 31 2025, total revenue was 54,731 thousand Canadian dollars, of which medical cannabis products contributed 53,186 thousand and other products contributed 1,545 thousand. The company sells to medical patients, licensed pharmacies and healthcare providers in both Israel and Germany.

The company operates through the following segments: Medical Cannabis Products and Other Products.

Medical Cannabis Products: This segment involves the importation, distribution and sale of medical cannabis flower and extracts to patients in Israel and Germany, including branded product lines such as IMC, BLK MKT and various high THC strains.
Other Products: This segment comprises the sale of cannabis accessories and related non cannabis items, such as products offered through partnerships with companies like Vessel Brand Inc.

The medical cannabis industry is highly competitive with competition varying by jurisdiction. In Israel, the company faces established local producers and brands, while in Germany it competes with licensed manufacturers and distributors ranging from large multinationals to new market entrants. Competitive advantages include the well known IMC brand, a cross border supply chain, regulatory expertise and EU GMP certified facilities that support product quality and reliability.

The company serves medical patients through its retail pharmacies and online platforms in Israel and supplies licensed pharmacies in Germany. Specific partners include Vessel Brand Inc. for accessory distribution in Israel, GlassHouse Botanics Inc. as a cannabis supplier in Germany and Avant Brands Inc. for brand licensing in the German market. The customer base consists primarily of patients with qualifying medical conditions and the pharmacies that dispense prescribed medical cannabis.

How IM Cannabis ranks

Ranked against the 40 companies in Tobacco and Cannabis58 metrics · as of Oct 16, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −0.13xMedian 16.3x 11^th
P/FCFNegative free cash flow −2.08xMedian 23.8x 9^th
P/Operating cash flowNegative operating cash flow −2.13xMedian 11.4x 9^th
P/S 0.03xMedian 0.92x 94^th
P/BNegative shareholder equity −0.26xMedian 1.01x Not meaningful —
P/Tangible bookNegative tangible equity −0.24xMedian 1.08x Not meaningful —
EV/EBITDANegative EBITDA −0.86xMedian 12.7x 4^th
EV/EBITNegative EBIT −0.77xMedian 18.3x 12^th
EV/Revenue 0.25xMedian 1.15x 91^st
EV/FCFNegative free cash flow −17.0xMedian 22.7x 34^th
EV/Operating cash flowNegative operating cash flow −17.4xMedian 14.2x 31^st
PEG (3Y EPS CAGR)Negative earnings 0.00Median 0.51 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) −11.9%Median 3.7% 21^st
Revenue CAGR (3Y) −6.6%Median −0.6% 25^th
Gross profit growth (1Y) −54.2%Median 2.2% 3^rd
Gross profit CAGR (3Y) −20.0%Median 3.2% 10^th
Operating income growth (1Y) −681%Median −8.1% 6^th
Operating income CAGR (3Y) 30.0%Median 27.2% 63^rd
Net income growth (1Y) −699%Median −9.3% 9^th
Net income CAGR (3Y) 52.6%Median 21.8% 79^th
EPS growth (1Y) −306%Median −8.5% 9^th
EPS CAGR (3Y) 66.8%Median 25.1% 85^th
Operating cash flow growth (1Y) −127%Median 14.4% 6^th
Operating cash flow CAGR (3Y) 64.8%Median 12.1% 87^th
Free cash flow growth (1Y) −129%Median 29.7% 6^th
Free cash flow CAGR (3Y) 65.3%Median 26.8% 88^th

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin 12.6%Median 43.3% 3^rd
EBITDA margin −29.3%Median 1.7% 11^th
Operating margin −33.0%Median −6.4% 18^th
Pretax margin −40.4%Median −14.1% 24^th
Net margin −23.5%Median −16.1% 35^th
FCF margin −1.5%Median 1.8% 38^th
Operating cash flow margin −1.5%Median 5.1% 34^th
Return on equity —Median −33.2% No data —
Return on assets −78.4%Median −13.4% 14^th
Return on invested capital —Median −4.4% No data —
Return on capital employed —Median −3.0% No data —
Asset turnover 1.93xMedian 0.59x 94^th
Cash conversion (OCF / net income)Net income is not positive 0.04xMedian 1.18x Not meaningful —
Stock comp / revenue —Median 2.3% No data —

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets 48.9%Median 22.4% 21^st
Debt / equityNegative shareholder equity −2.18xMedian 0.40x Not meaningful —
Net debt / EBITDAEBITDA is not positive −0.76xMedian 2.38x Not meaningful —
Debt / FCFFree cash flow is not positive −17.3xMedian 2.86x Not meaningful —
Liabilities / assets 122%Median 67.5% 13^th
Equity / assetsNegative shareholder equity −22.4%Median 32.5% 13^th
Interest coverage −2.02xMedian −2.88x 55^th
Current ratio 0.56xMedian 1.66x 14^th
Quick ratio 0.29xMedian 0.69x 16^th
Cash ratio 0.06xMedian 0.40x 8^th
Altman Z-score −16.5Median −1.20 19^th

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	PM	Philip Morris International Inc.	313.55 Bn	28.83	7.37	49.11 Bn
2	BTI	British American Tobacco p.l.c.	128.08 Bn	-	-	46.47 Bn
3	MO	Altria Group, Inc.	123.78 Bn	15.52	5.28	24.58 Bn
4	RLX	RLX Technology Inc.	2.10 Bn	35.44	3.00	0.02 Bn
5	CURLF	Curaleaf Holdings, Inc.	2.04 Bn	-63.89	1.56	0.61 Bn
6	TRLV	Trulieve Cannabis Corp.	1.98 Bn	-4.18	1.74	0.19 Bn
7	GTBIF	Green Thumb Industries Inc.	1.37 Bn	10.78	1.13	0.57 Bn
8	IMCC	IM Cannabis Corp.	0.00 Bn	-0.15	0.03	0.01 Bn

IM Cannabis IMCC

About

Segment consolidation items [axis] Breakdown of Revenue (2023)

Products and services [axis] Breakdown of Revenue (2023)

How IM Cannabis ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

IM Cannabis IMCC

About

Segment consolidation items [axis] Breakdown of Revenue (2023)

Products and services [axis] Breakdown of Revenue (2023)

How IM Cannabis ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password